Objective Our study aims to investigate the inhibitive effects of miR -124 on the growth of breast cancer cell MCF -7 induced by paclitaxel .Methods MTT was used to detect the growth inhibition of MCF-7 induced by paclitaxel .Flow cytometry was used to detect the effect of paclitaxel on cell cycle .Real-time quantitative PCR(qRT-PCR) was used to detect the expressive level of miR -124,while MCF -7 cells were treated with paclitaxel .MiR-124 inhibitor was transfected into MCF -7 breast cancer cells ,and growth in-hibition was detected by MTT .Results The results showed that paclitaxel could significantly inhibit the growth of breast cancer cell line MCF -7 by blocking the G2 phase.The results from qRT-PCR showed that the relative expression of miR-124 was increased when the dosage of paclitaxel was increased .When the expression of miR-124 was inhibited ,the cell growth inhibition caused by paclitaxel was also prominently decreased .Conclusion The higher expression of miR -124 in MCF-7 induced by paclitaxel was dose dependent .And miR-124 in-hibitor can significantly influence the cell growth inhibition caused by paclitaxel .These results indicat that miR -124 plays an important role in paclitaxel -induced chemotherapy drug resistance ,and provides a new direction to solve the problem .

MicroRNAs are non-coding small RNAs that participate in the regulation of post transcriptional gene expression.MicroRNAs play the roles of inhibiting cancer or promoting cancer in different tumors.MicroRNA-373 is one of the members of the microRNA-520/373 family,which is involved in cancer anoxic response and DNA damage repair.MicroRNA-373 is abnormal expressed in breast cancer,glioma,lung cancer,prostate cancer and other tumors,which may play an important role in tumor development process,especially in tumor invasion and migration.

Sulforaphane (SFN) is an isothiocyanate rich in cruciferous vegetables, and is one of the plant active substances with strong anticancer activity. SFN can protect cells from environmental carcinogens and induce growth arrest and apoptosis of various cancer cells. This article reviews the research progress of SFN in tumor prevention, treatment, and its role in tumor stem cells, explores the feasibility of SFN in clinical application for cancer prevention, and provides new strategies to reduce the development and recurrence of malignant tumors and improve patient survival.

Objective:To investigate the risk factors for lower extremity deep vein thrombosis (DVT) in patients with bone trauma and their diagnostic efficacy.Methods:A retrospective cohort study was conducted to analyze the clinical data of 108 patients with bone trauma who were admitted to Affiliated Changzhou Second People′s Hospital of Nanjing Medical University from October 2023 to February 2024, including 61 males and 47 females, aged 17-96 years [(55.2±19.5)years]. Based on the results of color Doppler ultrasonography of lower extremities within 96 hours on admission, the patients were divided into DVT group ( n=58) and non-DVT group ( n=50). In DVT group, 42 patients developed lower extremity DVT within 7 days after trauma and the other 16 patients developed lower extremity DVT after 7 days. Basic clinical data including gender, age, body mass index (BMI), underlying diseases, cause of injury, site of fracture, surgery and admission Caprini score, and admission laboratory test indicators including routine coagulation indicators [prothrombin time (PT), international normalized ratio (INR), thrombin time (TT), activated partial thromboplastin time (APTT), fibrinogen (FBG) and D-dimer (D-D)] and four thrombosis indicators [plasma thrombin-antithrombin III complex (TAT), thrombomodulin (TM), tissue-type plasminogen activator-inhibitor 1 complex (tPAIC) and plasmin-alpha2-plasmin inhibitor complex (PIC)] were collected in the two groups. Univariate analysis and multivariate binary Logistic regression analysis were conducted to investigate the correlation between these indicators and incidence of lower extremity DVT in patients with bone trauma and determine the independent risk factors. Receiver operating characteristic (ROC) curve and area under the curve (AUC) of the relevant risk factors were analyzed to evaluate and compare the diagnostic efficacy of the factors for lower extremity DVT in patients with bone trauma and further assess the diagnostic efficacy of the factors for lower extremity DVT within 7 days after bone trauma. Results:Univariate analysis revealed significant correlations of gender, age, Caprini score, D-D, TAT, TM and PIC with incidence of lower extremity DVT in patients with bone trauma ( P<0.01). The results of multivariate binary Logistic regression analysis demonstrated that Caprini score ( OR=1.36, 95% CI 1.12, 1.65, P<0.01), TAT ( OR=1.05, 95% CI 1.00, 1.10, P<0.05), and TM ( OR=1.34, 95% CI 1.02, 1.77, P<0.05) were significantly correlated to incidence of lower extremity DVT in patients with bone trauma. ROC curve analysis indicated that TAT (AUC=0.76, 95% CI 0.67, 0.86) had the highest diagnostic efficiency, followed by TM (AUC=0.72, 95% CI 0.62, 0.81) and Caprini score (AUC=0.72, 95% CI 0.62, 0.82). The combined analysis of all the factors effectively enhanced the diagnostic efficiency for DVT (AUC=0.84, 95% CI 0.77, 0.92). Additionally, TAT (AUC=0.81, 95% CI 0.71, 0.91) demonstrated better diagnostic efficacy for lower extremity DVT within 7 days after bone trauma compared with the Caprini score (AUC=0.72, 95% CI 0.61, 0.83) and TM (AUC=0.71, 95% CI 0.60, 0.83). Similarly, the combined analysis of all the factors also effectively enhanced the overall diagnostic efficacy for lower extremity DVT within 7 days after bone trauma (AUC=0.85, 95% CI 0.77, 0.93). Conclusions:Caprini score, TAT and TM are identified as independent risk factors for lower extremity DVT in patients with bone trauma, and all the three factors demonstrate good diagnostic efficacy. Their combination is found to have statistically significant higher diagnostic efficiency than each individual factor. Furthermore, TAT is proved to be the best in diagnosing lower extremity DVT within 7 days after bone trauma, while the combined analysis of all the risk factors can further improve the diagnostic efficacy.